ICYMI, some of this week’s featured content includes a new podcast episode on molecular targeting of biologics, and articles on pipeline updates for melanoma, treating various skin conditions in skin of color patients, and more.
At the Skin of Color Update 2021, Andrew Alexis, MD, MPH, presented on the subtle distinctions in treating skin of color patients with acne.
DermTech’s Pigmented Lesion Assay data was published in SKIN: The Journal of Cutaneous Medicine showing the results of its melanoma detection.
The FDA has approved halobetasol propionate foam, 0.05% (Lexette; Mayne Pharma), a potent topical corticosteroid, for the treatment of plaque psoriasis in adolescent patients.
Verrica Pharmaceuticals has received a complete response letter from the FDA identifying deficiencies at a manufacturing facility for VP-102.
In this exclusive video interview, Zoe Diana Draelos, MD, Dermatology Times chief medical editor, weighs in on the recent Black Box Warning issued by the FDA to certain JAK inhibitors.
Incyte announced the FDA has approved its topical selective Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib (Opzelura) for the treatment of mild to moderate atopic dermatitis.
Bristol Myers Squibb has announced that the FDA has accepted the Biologics License Application (BLA) for relatlimab and nivolumab, a fixed-dose combination treatment for unresectable or metastatic melanoma.
Possible melanoma treatments have had multiple newsworthy events since July 2021.
Catch up on all of the latest news coming out of the Skin of Color Update 2021.
The FDA has announced steps at improving the quality, safety, and efficacy of sunscreens.
A recent case report highlights the importance of caution when using fractional laser resurfacing in patients with active or previous acne.
A steady stream of novel therapeutic agents is now navigating the atopic dermatitis pipeline.
This week’s edition of The Mainstream Patient features stories about Botox stigma, treating skin of color patients, laser hair removal, skin care microdosing, plus more.
Investigators added that the meaning of each laboratory marker is dependent on the drug that is being used for treatment.
This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, the IL-17 drug class, how bimekizumab is different, plus more.
Even with patient hesitancy, treating PPP with gentian violet and chemical peels could help patients avoid biologics.
NEA’s Eczema Expo highlights new drugs, steroid withdrawal, alternative therapies.
In this week’s Pointers with Dr Portela, the 208SkinDoc and Cassandra Bankson, a medical aesthetician and skin advocate, react to cystic acne TikToks and offer commentary.
Hilary Baldwin, MD, presented on how to recognize, diagnose, and treat rosacea in patients with skin of color at the Skin of Color Update 2021.